15.5: Chemical Mediators of Digestion

Hormonal Regulation

The digestive process is regulated by a series of hormones secreted by specialized epithelial cells known as endocrinocytes. They are located in the mucosal epithelium of the stomach, and the first portion of the small intestine, especially the duodenum and jejunum, secrete these gastrointestinal hormones. They are released into the bloodstream, through which they can reach their target organs.

Gastrin is released by G cells in the antrum and duodenum and is a potent stimulator of gastric acid secretion. It activates parietal cells in the gastric glands, promoting the production and release of hydrochloric acid into the stomach lumen. This acidification of the gastric contents aids in the breakdown of food components and facilitates digestion. Gastrin interacts with histamine-producing enterochromaffin-like cells, causing these cells to release histamine. Histamine, in turn, acts synergistically with gastrin to induce the insertion of proton pumps (K⁺/H⁺-ATPase) into the parietal cell membrane, thereby enhancing gastric acid secretion. Several factors, including the presence of amino acids and small peptides in the stomach, stomach distension, and stimulation from the vagus nerve, trigger gastrin secretion. Somatostatin acts as an inhibitory regulator of gastrin release, playing a crucial role in preventing excessive gastric acid production. It counteracts the effects of gastrin along with other hormones such as insulin, glucagon, and histamine.

Cholecystokinin (CCK) is an important hormone involved in the digestive process, primarily originating from the mucosal cells (I cells) within the duodenum. CCK promotes the release of pancreatic enzymes, particularly lipase and protease, crucial for breaking down dietary fats and proteins present in chyme. CCK also plays a pivotal role in inducing the contraction of the gallbladder. This contraction is crucial as it enables the release of stored bile into the duodenum, facilitating the emulsification of fats. Additionally, CCK relaxes the sphincter of Oddi, a muscular valve controlling bile and pancreatic juice flow into the small intestine.

The presence of fatty acids and amino acids in chyme entering the duodenum acts as a potent stimulus for the release of CCK. As levels of these nutrients decline, the release of CCK is subsequently reduced. Somatostatin, produced by various gastrointestinal cells, including the delta cells of the pancreas, regulates CCK release. This inhibitory role of somatostatin helps to modulate and balance the secretion of CCK, fine-tuning the digestive process to maintain an optimal equilibrium.

Secretin, a hormone produced by S cells in the duodenum, plays a crucial role in stimulating the pancreas and liver to release bicarbonate-rich fluids, which are essential for neutralizing acidic chyme entering from the stomach. Often called "Nature's Antacid," secretin helps create an alkaline environment in the intestines, which is vital for optimal enzyme activity and protects the intestinal lining from acidity. It also enhances bile secretion from the liver, aiding in fat digestion. Additionally, secretin indirectly inhibits acid production in the stomach by stimulating the release of somatostatin, a regulatory hormone that reduces hydrogen ion secretion from parietal cells, thereby maintaining a balanced pH in the digestive system. Its release is triggered by the presence of acidic chyme in the duodenum, especially when the pH drops below 4.5, and is further stimulated by the presence of fatty acids.

Glucose-dependent Insulinotropic Peptide (GIP), primarily secreted by cells in the duodenum and proximal jejunum (K cells), is named for its role in stimulating insulin release in response to elevated blood glucose levels. GIP plays a crucial role in regulating various aspects of digestion. Its secretion is specifically triggered by the oral intake of glucose and other major nutrients; notably, intravenous glucose administration does not prompt GIP release. In addition to enhancing insulin secretion, GIP suppresses gastric acid production, slows gastric emptying, and reduces gastric motility, thereby helping to manage the rate of nutrient digestion and absorption.

Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone (hormone released by the gut in response to eating) secreted by enteroendocrine L-cells, primarily located in the distal ileum and colon, with lower concentrations in the jejunum. In recent years, its critical role in metabolic regulation has made it a target for type 2 diabetes and obesity therapies. GLP-1 regulates blood glucose through a glucose-dependent mechanism, stimulating pancreatic insulin secretion and suppressing glucagon release following meal ingestion. Beyond glycemic control, GLP-1 delays gastric emptying, which delays nutrient absorption and signals the hypothalamus to reduce appetite and promote satiety. Furthermore, it exerts positive cardiovascular effects, including modest reductions in blood pressure and improved endothelial function.

Motilin is a peptide hormone secreted by specialized enteroendocrine M-cells in the mucosa of the duodenum and proximal jejunum. It serves as the primary hormonal regulator of interdigestive gastrointestinal motility, operating exclusively during periods of fasting. Every 90 to 120 minutes between meals, a cyclical surge of motilin initiates the Migrating Motor Complex (MMC)—a distinct pattern of rhythmic, propulsive electrical waves that travel down the stomach and small intestine. The intense muscular contractions triggered are often called "housekeeping contractions." Their essential physiological function is to sweep undigested food remnants, cellular debris, and bacteria down the digestive tract, preventing bacterial overgrowth and preparing the gut for the next meal.

Paracrine Regulation

Somatostatin acts as a potent paracrine regulator within the gastrointestinal tract, exerting highly localized inhibitory control in the immediate vicinity of its release. Synthesized and secreted by specialized D-cells in the gastric mucosa, duodenal mucosa, and pancreatic islets, its release is stimulated by luminal acidity (such as acidic chyme) and suppressed by vagal cholinergic input (ACh). Known as the universal endocrine "off-switch," somatostatin curtails gastric acid production via a dual mechanism: it indirectly suppresses the release of pro-secretory gut hormones like gastrin and histamine, and directly binds to parietal cells to inhibit HCl secretion. This feedback loop is vital for preventing mucosal injury, halting excessive acid production, and maintaining optimal luminal homeostasis.

Histamine is a signaling molecule released by enterochromaffin-like cells in the stomach, where it plays a key role in stimulating gastric acid secretion. Upon binding to H2 receptors on parietal cells, histamine activates proton pumps, leading to an increase in hydrochloric acid secretion into the stomach lumen and raising gastric acidity. The release of histamine is stimulated by gastrin and ACh, while it is inhibited by somatostatin and prostaglandin E2. Acting as an intermediary, histamine bridges the initial signals from gastrin and ACh with the activation of acid secretion by parietal cells.

Neurotransmitters in Digestive Function

The gastrointestinal tract relies on a complex network of neurotransmitters and neuropeptides to coordinate motility, glandular secretion, and mesenteric blood flow. These chemical messengers operate through excitatory, inhibitory, or specialized modulatory pathways to maintain digestive homeostasis.

ACh serves as the principal neurotransmitter governing the "rest and digest" state, firing from parasympathetic and intrinsic enteric fibers to stimulate muscular contractions and accelerate glandular output. Working in tandem is serotonin (5-HT); synthesized predominantly by mucosal enterochromaffin (EC) cells, 5-HT acts as the primary sensory trigger. When food distends the gut wall or alters luminal pH, 5-HT is released to initiate the peristaltic reflex arc, propagate forward movement, and transmit real-time metabolic data back to the CNS via the vagus nerve. Where intense localized contraction is required, substance P is co-released with ACh, simultaneously driving smooth muscle constriction and regulating local inflammatory and pain pathways. Conversely, NE handles sympathetic braking. During periods of physical stress, NE halts non-essential digestive functions by relaxing the intestinal walls, shutting down secretions, and constricting local vasculature to redirect blood to skeletal muscle. Within the gut's local circuitry, Nitric oxide (NO) works as a potent non-adrenergic, non-cholinergic relaxation agent, enabling sphincters to open and allowing the descending limb of a peristaltic wave to relax ahead of oncoming food. Dopamine and GABA act as internal modulators within the enteric nerve plexuses, dampening excessive smooth muscle firing, stabilizing motility rhythms, and keeping visceral hypersensitivity in check.

Peptides like gastrin-releasing peptide (GRP) provide highly targeted regulation, acting almost exclusively to signal G-cells in the stomach to dump gastrin, which triggers hydrochloric acid production. Vasoactive intestinal peptide (VIP) relaxes major muscular boundaries like the lower esophageal sphincter to allow smooth passage of contents, suppresses further gastric hydrogen ion secretion to neutralize pH, and stimulates the release of pancreatic bicarbonate to protect the intestinal lining.^{1, 8-9, 11} 

Enkephalins and endorphins serve as principal inhibitory neuropeptides within the enteric nervous system, acting primarily to suppress gastrointestinal motility and decrease mucosal secretion. While they inhibit the coordinated, propulsive relaxation of longitudinal smooth muscle, they stimulate sustained, tonic contraction of circular smooth muscle and GI sphincters. This dual mechanism markedly delays gastric emptying and brings peristalsis to a halt, while simultaneously inhibiting the active secretion of intestinal fluids and electrolytes into the lumen. This profound antisecretory and antimotility profile forms the physiological basis for using therapeutic opiates to manage severe diarrhea, whereas excessive activation of these pathways naturally precipitates constipation.

During the perioperative period, these pathways are heavily manipulated, as anesthetics and exogenous mu-opioid receptor agonists administered for surgical pain management—such as morphine and fentanyl—mimic endogenous enkephalins. By binding directly to enteric opioid receptors, these drugs blunt mucosal secretory reflexes and disrupt coordinated motor patterns, frequently causing opioid-induced constipation (OIC). Ultimately, alongside the physical manipulation of the intestines and localized inflammatory responses during surgery, this intense opioid-driven inhibition of the enteric neural circuitry stands as a primary contributing factor to postoperative ileus, the temporary cessation of bowel motility commonly observed after surgical procedures.¹²